Drew Altman: 3 Takeaways From the Medicare Trustees Report August 1, 2014 News Release In his latest column for The Wall Street Journal’s Think Tank, Drew Altman dives into this week’s release of the Social Security and Medicare Trustees Report to discuss the good news that may have been missed. All previous columns by Drew Altman are available online.
3 Takeaways From the Medicare Trustees Report August 1, 2014 Perspective In his latest column for The Wall Street Journal’s Think Tank, Drew Altman dives into this week’s release of the Social Security and Medicare Trustees Report to discuss the good news that may have been missed.
The Growth in Share of Medicare Advantage Spending April 7, 2022 Slide Earlier this week, the Biden Administration announced the final Medicare Advantage rates for 2023, which are projected to result in an average increase in Medicare Advantage plan revenue of 8.5% compared to 2022 – the highest average expected increase in recent years. Payments to Medicare Advantage plans as a share…
Implications of the Lapse in Federal COVID-19 Funding on Access to COVID-19 Testing, Treatment, and Vaccines March 28, 2022 Issue Brief A current impasse in Congress threatens continued funding for COVID-19 testing, treatment, and vaccines. The lack of additional federal COVID-19 funding has broad implications for access to these services, particularly for the uninsured, and could undermine efforts to ensure equitable access to these resources.
U.S. Global Funding for COVID-19 by Country and Region: An Analysis of USAID Data June 29, 2022 Issue Brief As Congress again considers increased assistance for the global response to COVID-19, we look at how current U.S. global COVID-19 emergency funding is being channeled, particularly to countries and regions.
Dec. 8 Event: Unpacking the Prescription Drug Provisions of the Build Back Better Act December 8, 2021 Event As the Build Back Better Act shifts from the House to the Senate, there’s considerable interest in provisions that would lower the cost of prescription drugs. The House-passed bill would allow the federal government to negotiate prices for some high-cost drugs in Medicare, and set a hard cap on out-of-pocket…
Analysis Compares President Trump and Democratic Nominee Biden on COVID-19 September 11, 2020 News Release Few issues are likely to matter as much to voters in November’s presidential election as President Trump’s response to the COVID-19 pandemic and resulting economic crisis, which have left almost 200,000 Americans dead and prompted job layoffs and furloughs affecting tens of millions of Americans. A new election brief compares…
Comparing Trump and Biden on COVID-19 September 11, 2020 Issue Brief This issue brief compares President Trump and Democratic nominee Joe Biden on their records, actions and proposals related to the COVID-19 pandemic. It includes a general overview of their respective approaches, followed by a detailed side-by-side.
The Coronavirus Aid, Relief, and Economic Security Act: Summary of Key Health Provisions April 9, 2020 Issue Brief This summary of the Coronavirus Aid, Relief, and Economic Security (CARES) Act highlights and summarizes health-related provisions focused on the COVID-19 outbreak in the United States and support for the global response.
U.S. Global Funding for COVID-19 by Country and Region October 23, 2020 Issue Brief This data note examines the status of U.S. global COVID-19 country, regional, and worldwide funding to assess how much has been committed to date and where it has been directed.